# Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema

> **NCT00716053** · PHASE3 · WITHDRAWN · sponsor: **Aeris Therapeutics** · enrollment: 225 (estimated)

## Conditions studied

- Advanced Upper Lobe Predominant Emphysema

## Interventions

- **DRUG:** BLVR

## Key facts

- **NCT ID:** NCT00716053
- **Lead sponsor:** Aeris Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-12
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2010-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00716053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00716053, "Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00716053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*